Clinical trials: Usual Care
Hemophilia B, Hemophilia A
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
To establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study.
- Trial name
- NCT03587116
- Testing
- Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy
- Where
- 75 sites in United States, Australia and 16 more
- Volunteers
- 212 people
- Sponsor
- Pfizer
Hemophilia A
Study Evaluating Refacto For Pharmacovigilance
The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.
- Trial name
- NCT00195442
- Testing
- Moroctocog alfa
- Where
- 26 sites in Austria, Germany
- Volunteers
- 288 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy…
- Trial name
- NCT01277523
- Testing
- tiotropium high dose, tiotropium low dose
- Where
- 69 sites in United States, Argentina and 12 more
- Volunteers
- 392 people
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome
Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome
This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using a treatment paradigm similar…
- Trial name
- ALPACS (NCT00728988)
- Testing
- Atorvastatin
- Where
- 26 sites in China, South Korea
- Volunteers
- 499 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatment without added…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
- Trial name
- NCT01031680
- Testing
- Dapagliflozin
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 922 people
- Sponsor
- AstraZeneca
Asthma
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult…
- Trial name
- PERFORM (NCT06372496)
- Testing
- Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
- Where
- 117 sites in United States, Argentina and 6 more
- Volunteers
- 1,358 people
- Sponsor
- GlaxoSmithKline
Hemophilia A
Study Evaluating The Safety Of Xyntha In Usual Care Settings
The purpose of this study is to collect safety information associated with the use of Xyntha in a usual care setting. Upon meeting eligibility criteria, patients will be required to have approximately 5 study visits over a 2 year…
- Trial name
- NCT00765726
- Testing
- Moroctocog alfa(AF-CC), Blood draw for laboratory testing
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 12 people
- Sponsor
- Pfizer
Neuromuscular Blockade, Arthroplasty, Replacement, Hip
Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)
This study will assess the effect of reversal of neuromuscular blockade with sugammadex compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of post-surgical bleeding events and on…
- Conditions
- Neuromuscular Blockade, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Blood Coagulation
- Trial name
- NCT01422304
- Testing
- Sugammadex, neostigmine and glycopyrrolate or atropine
- Volunteers
- 1,198 people
- Sponsor
- Merck Sharp & Dohme LLC
Hemophilia A
PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
An open-label, single-arm, post- authorization pragmatic clinical trial on the safety and efficacy of Xyntha (Moroctocog-alfa (AF-CC), Recombinant FVIII) in subjects with hemophilia A in usual care settings in China for…
- Trial name
- NCT02492984
- Testing
- Intravenous infusions of Xyntha
- Where
- 15 sites in China
- Volunteers
- 85 people
- Sponsor
- Pfizer
Asthma
Asthma Control Test Guided Treatment in Chinese Subjects
This study is aimed to evaluate the effectiveness of Asthma Control Test (ACT) guided treatment compared with usual care in asthma subjects in China.
- Trial name
- NCT02868281
- Testing
- ACT guided Routine Treatment, Routine Treatment
- Where
- 6 sites in China
- Volunteers
- 530 people
- Sponsor
- GlaxoSmithKline
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Hypertension, Hypercholesterolemia
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
- Trial name
- CRUCIAL (NCT00407537)
- Testing
- Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 125 sites in Costa Rica, Croatia and 18 more
- Volunteers
- 1,531 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Lymphedema, Lymphedema of Face
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
To compare the effectiveness of an APCD to Usual Care in the management of lymphedema and fibrosis (LEF) in head and neck cancer (HNC) survivors.
- Conditions
- Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation
- Trial name
- NCT04797390
- Testing
- Advanced Pneumatic Compression Device (APCD), Usual Care
- Where
- 10 sites in United States
- Volunteers
- 236 people
- Sponsor
- Tactile Medical
Hemophilia B
Registry For Patients Treated With BeneFix In Usual Care Setting In Germany
The purpose of this observational study is to describe the incidence of adverse events among patients treated with BeneFix® in usual health care settings in Germany.
- Trial name
- NCT00714415
- Testing
- BeneFIX
- Where
- 21 sites in Austria, Germany
- Volunteers
- 80 people
- Sponsor
- Pfizer
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
The purpose of this study is to evaluate the safety and effectiveness of etanercept under usual care settings in patients with PsA treated by rheumatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293722
- Testing
- Etanercept
- Where
- Germany
- Volunteers
- 1,308 people
- Sponsor
- Pfizer
Hemophilia A
Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings
The study will be investigating safety in patients who switch to ReFacto AF from ReFacto and other Factor VIII products.
- Trial name
- NCT00884390
- Testing
- moroctocog alfa (AF-CC) (ReFacto AF), Laboratory tests
- Where
- 74 sites in Austria, Belgium and 12 more
- Volunteers
- 208 people
- Sponsor
- Pfizer
HEMOPHILIA B
Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China
The purpose of this post-approval study is to evaluate the safety and efficacy of Benefix in subjects with hemophilia B in usual care settings in China.
- Trial name
- NCT02336178
- Testing
- Benefix
- Where
- 16 sites in China
- Volunteers
- 70 people
- Sponsor
- Pfizer
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis
Paricalcitol capsules (Zemplar®) received marketing authorization in Sweden in late 2007 for the prevention and treatment of secondary hyperparathyroidism in patients with Stage 3 \& 4 Chronic Kidney Disease (CKD).
- Trial name
- CAPITOL (NCT01265992)
- Where
- 10 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Pulmonary Disease, Chronic Obstructive
INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design
The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA Multiple Inhaler Triple Therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual…
- Trial name
- NCT03467425
- Testing
- FF/UMEC/VI, Inhaled Corticosteroid, LAMA
- Where
- 143 sites in Germany, Netherlands and 3 more
- Volunteers
- 3,109 people
- Sponsor
- GlaxoSmithKline